The US Food and Drug Administration approved five original PMAs in November.
The agency approved Axonics Modulation Technologies Inc.’s r-SNM rechargeable sacral neuromodulation system for treating overactive bladder and urinary retention on 14 November. The agency approved the same device for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?